Document Detail

Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angiotensin blockers.
MedLine Citation:
PMID:  16907653     Owner:  NLM     Status:  MEDLINE    
Angiotensin (Ang) II plays important roles in the development of hypertension and cardiovascular and renal injury. Pharmaceutical approaches to block its activity led to the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Numerous trials have documented their efficacy in controlling blood pressure, minimising left ventricular remodelling, preventing progression to heart failure, ameliorating proteinuria and retarding renal disease progression. Although they are considered safe in general, there remain concerns about the potential for adverse events in certain target populations. Recently, several novel, low molecular weight renin inhibitors without the extended peptide-like backbone of previous renin inhibitors were developed with favourable pharmacokinetic properties. They have been shown to successfully reduce Ang II levels in normal volunteers and to lower blood pressure in patients with mild-to-moderate hypertension. In this review, the authors summarise current knowledge about these renin inhibitors.
Huifang Cheng; Raymond C Harris
Related Documents :
21516243 - The triad of idiopathic normal-pressure hydrocephalus a clinical practice case report.
20046983 - Collecting duct renin: a major player in angiotensin ii-dependent hypertension.
20689333 - Physical and physiological effects on otoacoustic emissions in hypobaric hypoxia.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  5     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-15     Completed Date:  2006-08-23     Revised Date:  2008-04-14    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  631-41     Citation Subset:  IM    
George M. O'Brien Kidney and Urologic Diseases Center and Division of Nephrology, Vanderbilt University School of Medicineand Nashville Veterans Affairs Hospital, Nashville, TN 37232, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Drug-Induced / etiology
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Clinical Trials as Topic
Fumarates / adverse effects,  therapeutic use
Hyperkalemia / chemically induced*
Hypertension / drug therapy*
Hypotension / chemically induced*
Inappropriate ADH Syndrome / chemically induced
Receptors, Angiotensin / antagonists & inhibitors*
Renin / antagonists & inhibitors*,  physiology
Reg. No./Substance:
0/Amides; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Fumarates; 0/Receptors, Angiotensin; 0/aliskiren; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cardiac dysfunction associated with trastuzumab.
Next Document:  Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it.